Research programme: small molecule lipid mediators - Resolvyx Pharmaceuticals

Drug Profile

Research programme: small molecule lipid mediators - Resolvyx Pharmaceuticals

Alternative Names: NPD 1; Resolvin D1; RvD 1; RX-05 - Resolvyx; RX-10005; RX-10008; RX-10065; RX-20001; RX-65

Latest Information Update: 04 May 2016

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Resolvyx Pharmaceuticals
  • Class Omega 3 fatty acids; Small molecules
  • Mechanism of Action Inflammation mediator inhibitors; Lipid modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Age-related macular degeneration; Dry eyes; Inflammation

Most Recent Events

  • 04 May 2016 Discontinued - Preclinical for Age-related macular degeneration in USA (Topical)
  • 04 May 2016 Discontinued - Preclinical for Dry eyes in USA (Topical)
  • 04 May 2016 Discontinued - Preclinical for Inflammation in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top